Olema Pharmaceuticals (OLMA) Stock Jumps 9% Following Fourth Quarter Earnings Surprise

TLDR

• Olema Pharmaceuticals (OLMA) shares surged 8.5% Monday following a Q4 earnings beat, posting a loss of $0.50 per share versus the anticipated $0.51.
• The biotech firm recorded a GAAP net loss of $46.1 million in Q4 2025 and $162.5 million across the full fiscal year.
• Stifel maintained its Buy rating with a $48 price target post-earnings, highlighting the company’s cash reserves lasting through mid-2028.
• Roche’s recent persevERA trial failure has sparked concerns regarding Olema’s OPERA-02 trial prospects.
• Wall Street consensus leans “Moderate Buy” with a mean price target of $41, while shares are down 41% YTD despite a 234% surge over the trailing year.

Olema Pharmaceuticals (OLMA) shares rallied 8.5% during Monday’s trading session following the release of fourth-quarter results that narrowly topped analyst projections. The stock peaked at $16.07 intraday before closing near $15.96, marking a solid gain from the previous close of $14.71.

Olema Pharmaceuticals, Inc., OLMA

The biopharmaceutical company disclosed a quarterly loss of $0.50 per share for Q4 2025, surpassing the Street’s expectation of a ($0.51) loss by one cent. While modest, the earnings surprise proved sufficient to drive investor enthusiasm.

For fiscal year 2025, Olema recorded a GAAP net loss totaling $162.5 million. The fourth quarter alone contributed $46.1 million to that deficit. Management opted not to host an earnings conference call following the release.

The stock’s performance has been nothing short of volatile. While OLMA has delivered a remarkable 234% return over the past twelve months, shares had tumbled 41% year-to-date prior to Monday’s rally.

Trading activity registered at 518,220 shares — significantly below the stock’s typical daily volume of approximately 1.6 million. The subdued volume suggests investors may be proceeding cautiously rather than piling in aggressively.

Analyst Reaction

Stifel responded swiftly to the earnings release, reaffirming its Buy rating and $48 price objective. The firm emphasized Olema’s financial runway stretching into mid-2028 as a significant advantage, providing adequate resources to reach several critical milestones ahead of palazestrant’s anticipated commercial debut.

Palazestrant is currently in development for second- and third-line metastatic breast cancer treatment, with market entry projected for 2027.

The broader analyst community maintains an optimistic outlook. Ten analysts have assigned Buy ratings to the stock, with one Hold and one Sell rating. The consensus price target stands at $41.00 — representing substantial upside from current trading levels.

Oppenheimer reaffirmed its Outperform rating on March 9th. JPMorgan lifted its price target from $29 to $32 last November, maintaining an Overweight stance. TD Cowen also holds a Buy rating, highlighting palazestrant’s superior exposure compared to rival therapies.

H.C. Wainwright reduced its target to $38 but retained its Buy rating in response to recent clinical trial developments.

The Roche Factor

Earlier this month, Roche announced that its persevERA clinical trial — assessing giredestrant combined with palbociclib in first-line metastatic breast cancer patients — failed to achieve statistical significance on its primary progression-free survival endpoint. While a favorable numerical trend was observed, the miss carries significant implications.

The persevERA outcome is considered a potential indicator for Olema’s own Phase 3 OPERA-02 trial, which is evaluating palazestrant. Topline results from OPERA-02 aren’t anticipated until 2028 at the earliest.

Stifel noted that Roche’s complete persevERA dataset will likely be unveiled at ASCO 2026, which could represent the next significant catalyst — or obstacle — for OLMA shares.

Regarding financial health, Olema maintains a stronger cash position than debt, boasting a current ratio of 8.03. The stock’s 50-day moving average currently sits at $24.18, considerably above Monday’s trading range.

Institutional ownership accounts for 91.78% of outstanding shares. Meanwhile, company insiders have been net sellers — divesting approximately 805,501 shares valued at roughly $23 million during the past three months.

The company currently commands a market capitalization of approximately $1.09 billion.

The post Olema Pharmaceuticals (OLMA) Stock Jumps 9% Following Fourth Quarter Earnings Surprise appeared first on Blockonomi.